A Randomized Controlled Study of Ferric Carboxymaltose versus Placebo in Patients with Heart Failure on Short Term Outcomes including quality of life, exercise tolerance, hemodynamic indices, serum BNP and ST2 levels

Trial Profile

A Randomized Controlled Study of Ferric Carboxymaltose versus Placebo in Patients with Heart Failure on Short Term Outcomes including quality of life, exercise tolerance, hemodynamic indices, serum BNP and ST2 levels

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Sep 2016 Status changed from recruiting to discontinued.
    • 17 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top